<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=1400074&amp;fmt=gif">

Press Releases

Jump to a page: News Media Kit

Biodesix Names Dr. James Jett Chief Medical Officer

Biodesix, Inc. the leader in lung cancer diagnostics, today announced the appointment of internationally recognized lung cancer expert, James Jett, M.D., as Chief Medical Officer.

Biodesix Secures U.S. Patent for Proprietary Blood Specimen Collection Device

Biodesix, Inc., today announced it has been issued U.S. Patent Number 10,422,729, which covers the Biodesix Collection Device (BCD). The new device offers improved ease of use in blood sample collection for diagnostic testing, compared to current standard methods.

Biodesix Highlights Pipeline and Companion Diagnostic Development at World CDx and RAS-Targeted Drug Discovery

Biodesix highlighted the company’s capabilities in the development and commercialization of companion diagnostics aimed at directing the treatment of non-small cell lung cancer (NSCLC) at the 2019 Clinical Biomarkers & World CDx Conference.

Biodesix Announces New Clinical Data Demonstrating VeriStrat Testing Predicts Survival in Advanced NSCLC and Immunotherapy

Biodesix, Inc. this week highlighted findings from multiple studies demonstrating the significance and clinical utility of its VeriStrat® blood-based proteomic test.

Biodesix Adds Dr. Robert Georgantas III to Executive Leadership Team

Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex

Biodesix Adds Dr. Charles Watts to Board of Directors

Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex

Biodesix, Immodulon Collaborating on Pancreatic Cancer Biomarkers

Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex

Biodesix Reaches Agreement to Deliver Next-Generation Sequencing Assay for Blood-Based Companion Diagnostic Solutions in Cancer

Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex

Biodesix to Acquire Oncimmune in the United States

Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex

Biodesix Previews Data for Osimertinib Resistance and Precision of Liquid Biopsy at AACR

Biodesix announced a biomarker research collaboration with Checkmate Pharmaceuticals, using Biodesix's proprietary discovery platform, the Diagnostic Cortex